TRVI vs. VNDA, CARA, PTI, ALXO, CALT, DNTH, SLN, ANAB, AVBP, and HROW
Should you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Vanda Pharmaceuticals (VNDA), Cara Therapeutics (CARA), Proteostasis Therapeutics (PTI), ALX Oncology (ALXO), Calliditas Therapeutics AB (publ) (CALT), Dianthus Therapeutics (DNTH), Silence Therapeutics (SLN), AnaptysBio (ANAB), ArriVent BioPharma (AVBP), and Harrow (HROW). These companies are all part of the "medical" sector.
Vanda Pharmaceuticals (NASDAQ:VNDA) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
Vanda Pharmaceuticals has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.
Trevi Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 235.97%. Given Vanda Pharmaceuticals' higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than Vanda Pharmaceuticals.
88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 7.7% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 24.4% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Trevi Therapeutics has a net margin of 0.00% compared to Trevi Therapeutics' net margin of -2.75%. Trevi Therapeutics' return on equity of -0.90% beat Vanda Pharmaceuticals' return on equity.
Vanda Pharmaceuticals received 456 more outperform votes than Trevi Therapeutics when rated by MarketBeat users. Likewise, 68.55% of users gave Vanda Pharmaceuticals an outperform vote while only 60.94% of users gave Trevi Therapeutics an outperform vote.
In the previous week, Trevi Therapeutics had 3 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 8 mentions for Trevi Therapeutics and 5 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.03 beat Trevi Therapeutics' score of 0.30 indicating that Trevi Therapeutics is being referred to more favorably in the news media.
Vanda Pharmaceuticals has higher revenue and earnings than Trevi Therapeutics. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Trevi Therapeutics beats Vanda Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Trevi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trevi Therapeutics Competitors List
Related Companies and Tools
